Y-mAbs Therapeutics (YMAB) Short Interest Ratio & Short Volume $14.31 +1.30 (+9.99%) (As of 09/17/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Y-mAbs Therapeutics Short Interest DataY-mAbs Therapeutics (YMAB) has a short interest of 4.19 million shares, representing 11.35% of the float (the number of shares available for trading by the public). This marks a -12.71% decrease in short interest from the previous month. The short interest ratio (days to cover) is 15.0, indicating that it would take 15.0 days of the average trading volume of 304,660 shares to cover all short positions.Current Short Interest4,190,000 sharesPrevious Short Interest4,800,000 sharesChange Vs. Previous Month-12.71%Dollar Volume Sold Short$59.96 millionShort Interest Ratio15.0 Days to CoverLast Record DateAugust 31, 2024Outstanding Shares43,883,000 sharesFloat Size36,920,000 sharesShort Percent of Float11.35%Today's Trading Volume316,236 sharesAverage Trading Volume304,660 sharesToday's Volume Vs. Average104% Short Selling Y-mAbs Therapeutics? Sign up to receive the latest short interest report for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartYMAB Short Interest Over TimeYMAB Days to Cover Over TimeYMAB Percentage of Float Shorted Over Time Ad Monetary GoldBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. Y-mAbs Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/31/20244,190,000 shares $59.96 million -12.7%11.4%15 $14.31 8/15/20244,800,000 shares $58.61 million +3.0%13.0%16.9 $12.21 7/31/20244,660,000 shares $57.22 million +9.9%12.9%14.8 $12.28 7/15/20244,240,000 shares $55.04 million +18.1%11.7%12.5 $12.98 6/30/20243,590,000 shares $43.37 million -1.9%9.9%10.1 $12.08 6/15/20243,660,000 shares $43.59 million +7.3%10.1%10.5 $11.91 Get the Latest News and Ratings for YMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/31/20243,410,000 shares $41.26 million -10.0%9.4%9.3 $12.10 5/15/20243,790,000 shares $46.16 million +52.8%9.9%10.3 $12.18 4/30/20242,480,000 shares $37.72 million +6.4%7.5%6.3 $15.21 4/15/20242,330,000 shares $34.74 million +4.0%7.0%5.9 $14.91 3/31/20242,240,000 shares $36.42 million +6.7%6.8%5.3 $16.26 3/15/20242,100,000 shares $30.87 million -3.2%6.4%5.3 $14.70 2/29/20242,170,000 shares $36.24 million -1.4%6.6%5.6 $16.70 2/15/20242,200,000 shares $35.20 million -2.2%6.7%6.2 $16.00 1/31/20242,250,000 shares $28.78 million +5.6%6.8%7.3 $12.79 1/15/20242,130,000 shares $20.55 million -7.8%6.4%8.3 $9.65 12/31/20232,310,000 shares $15.75 million +6.9%6.9%11.3 $6.82 12/15/20232,160,000 shares $14.32 million -13.3%6.5%10.6 $6.63 11/30/20232,490,000 shares $15.46 million -2.4%7.4%13.7 $6.21 11/15/20232,550,000 shares $13.39 million +2.0%7.6%14.9 $5.25 10/31/20232,500,000 shares $13.35 million -4.2%7.6%13.7 $5.34 10/15/20232,610,000 shares $13.83 million -2.6%7.9%13.6 $5.30 9/30/20232,680,000 shares $14.61 million -2.9%8.1%14.9 $5.45 9/15/20232,760,000 shares $13.77 million +6.2%8.4%14.6 $4.99 8/31/20232,600,000 shares $13.18 million -17.2%7.9%11.9 $5.07 8/15/20233,140,000 shares $17.90 million +52.4%9.5%12.8 $5.70 7/31/20232,060,000 shares $12.55 million +6.7%6.1%7 $6.09 7/15/20231,930,000 shares $13.68 million +7.2%5.8%6.3 $7.09 6/30/20231,800,000 shares $12.22 million +2.3%5.5%5.1 $6.79 6/15/20231,760,000 shares $14.10 million +6.7%5.3%2.4 $8.01 5/31/20231,650,000 shares $13.41 million -8.3%5.0%2.3 $8.13 5/15/20231,800,000 shares $18.50 million -2.7%5.5%2.4 $10.28 4/30/20231,850,000 shares $11.08 million +3.4%5.6%2.6 $5.99 4/15/20231,790,000 shares $11.71 million -28.4%5.4%2.6 $6.54 3/31/20232,500,000 shares $12.53 million +26.9%7.6%3.7 $5.01 3/15/20231,970,000 shares $6.64 million +10.7%5.6%6.3 $3.37 2/28/20231,780,000 shares $6.76 million -3.3%5.0%4.7 $3.80 2/15/20231,840,000 shares $7.91 million -5.2%5.2%4.7 $4.30 1/31/20231,940,000 shares $8.71 million +1.0%5.5%4 $4.49 1/15/20231,920,000 shares $9.16 million -0.5%5.5%2.8 $4.77Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. 12/30/20221,930,000 shares $9.42 million +14.2%5.5%2.8 $4.88 12/15/20221,690,000 shares $8.75 million -1.7%4.8%2.4 $5.18 11/30/20221,720,000 shares $7.69 million +17.0%4.9%2.7 $4.47 11/15/20221,470,000 shares $6.56 million -52.3%4.2%2.4 $4.46 10/31/20223,080,000 shares $11.12 million -17.0%8.7%5.8 $3.61 10/15/20223,710,000 shares $53.50 million -1.6%10.5%13.5 $14.42 9/30/20223,770,000 shares $54.36 million -2.3%10.7%13.5 $14.42 9/15/20223,860,000 shares $55.97 million +2.1%10.9%13.6 $14.50 8/31/20223,780,000 shares $60.78 million +1.1%10.7%11.5 $16.08 8/15/20223,740,000 shares $70.39 million +5.4%10.6%10.5 $18.82 7/31/20223,550,000 shares $55.34 million +2.9%10.1%8.3 $15.59 7/15/20223,450,000 shares $57.41 million -4.7%9.8%7.3 $16.64 6/30/20223,620,000 shares $54.77 million -9.7%10.3%7.6 $15.13 6/15/20224,010,000 shares $46.36 million -4.3%11.4%8.8 $11.56 5/31/20224,190,000 shares $52.12 million +1.2%11.9%9 $12.44 5/15/20224,140,000 shares $42.64 million +43.3%11.8%8.6 $10.30 4/30/20222,890,000 shares $24.28 million -1.7%8.2%3.9 $8.40 4/15/20222,940,000 shares $37.69 million +3.9%8.4%3.9 $12.82 3/31/20222,830,000 shares $33.62 million +25.2%8.1%3.7 $11.88 3/15/20222,260,000 shares $19.66 million -5.8%6.4%3 $8.70 2/28/20222,400,000 shares $21.86 million -6.6%6.8%3.4 $9.11 2/15/20222,570,000 shares $20.82 million +31.1%7.3%3.7 $8.10 1/31/20221,960,000 shares $19.38 million No Change5.7%5 $9.89 1/15/20221,960,000 shares $23.76 million +2.1%5.7%6.8 $12.12 12/31/20211,920,000 shares $31.12 million -6.8%5.6%8.5 $16.21 12/15/20212,060,000 shares $34.20 million -7.2%6.0%9.6 $16.60 11/30/20212,220,000 shares $37.92 million -7.9%6.5%11.4 $17.08 11/15/20212,410,000 shares $52.78 million -9.1%7.0%13.2 $21.90 10/29/20212,650,000 shares $65.08 million +7.7%7.7%14.3 $24.56 10/15/20212,460,000 shares $65.63 million +1.2%7.2%13.2 $26.68 9/30/20212,430,000 shares $69.35 million -10.3%7.1%11.8 $28.54 9/15/20212,710,000 shares $91.73 million +2.3%7.9%12.6 $33.85 8/31/20212,650,000 shares $81.57 million -12.0%7.7%11.1 $30.78 8/13/20213,010,000 shares $87.56 million +2.7%8.8%11.9 $29.09 7/30/20212,930,000 shares $96.98 million +4.3%8.5%11.4 $33.10 7/15/20212,810,000 shares $87.59 million -1.8%8.2%10.8 $31.17 6/30/20212,860,000 shares $96.67 million -4.4%8.4%10.6 $33.80 6/15/20212,990,000 shares $103.39 million -4.5%8.8%10.3 $34.58 5/28/20213,130,000 shares $112.15 million -3.1%9.3%10.6 $35.83 5/14/20213,230,000 shares $105.78 million +7.7%9.6%10.1 $32.75 4/30/20213,000,000 shares $89.07 million -1.6%8.9%8.9 $29.69 4/15/20213,050,000 shares $81.71 million -15.8%10.8%9.7 $26.79 3/31/20213,620,000 shares $107.08 million +27.9%12.8%11.8 $29.58 3/15/20212,830,000 shares $101.94 million -2.4%10.0%9.7 $36.02 2/26/20212,900,000 shares $97.67 million +30.0%10.7%10.9 $33.68 2/12/20212,230,000 shares $106.77 million -24.2%8.3%8.9 $47.88 1/29/20212,940,000 shares $125.30 million -2.7%11.7%13.2 $42.62 1/15/20213,020,000 shares $150.94 million -1.6%12.0%13.8 $49.98 12/31/20203,070,000 shares $153.53 million -12.5%12.2%15.3 $50.01 12/15/20203,510,000 shares $183.19 million +0.3%13.9%17.1 $52.19Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. 11/30/20203,500,000 shares $168.67 million +1.7%14.0%19.1 $48.19 10/30/20203,350,000 shares $145.26 million +2.8%13.4%23 $43.36 10/15/20203,260,000 shares $129.85 million +11.6%13.2%21.6 $39.83 9/30/20202,920,000 shares $112.10 million +15.4%11.9%18.2 $38.39 9/15/20202,530,000 shares $99.61 million -0.4%10.3%14.6 $39.37 8/31/20202,540,000 shares $109.30 million -4.2%10.3%13.7 $43.03 8/14/20202,650,000 shares $103.38 million -0.8%10.8%12.2 $39.01 7/31/20202,670,000 shares $93.80 million +3.9%10.9%10.7 $35.13 7/15/20202,570,000 shares $102.34 million +2.4%10.6%10.3 $39.82 6/30/20202,510,000 shares $108.43 million +12.6%10.3%9.9 $43.20 6/15/20202,230,000 shares $93.95 million +4.7%9.2%9.3 $42.13 5/29/20202,130,000 shares $81.32 million -2.3%8.8%8 $38.18 5/15/20202,180,000 shares $84.15 million -5.6%9.0%8.4 $38.60 4/30/20202,310,000 shares $77.57 million +0.4%9.7%10.3 $33.58 4/15/20202,300,000 shares $69.09 million +14.4%9.3%10.4 $30.04 3/31/20202,010,000 shares $52.46 million +2.0%8.2%8.8 $26.10 3/13/20201,971,200 shares $57.50 million +15.3%15.6%6.3 $29.17 2/28/20201,710,000 shares $33.04 million +30.5%13.5%7.8 $19.32 2/14/20201,310,000 shares $33.08 million -3.0%5.3%6.1 $25.25 1/31/20201,350,000 shares $40.64 million -10.0%6.9%5.6 $30.10 1/15/20201,500,000 shares $49.89 million -9.1%7.7%5.3 $33.26 12/31/20191,650,000 shares $58.01 million +55.7%8.3%6 $35.16 YMAB Short Interest - Frequently Asked Questions What is Y-mAbs Therapeutics' current short interest? Short interest is the volume of Y-mAbs Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 4,190,000 shares of YMAB short. 11.35% of Y-mAbs Therapeutics' shares are currently sold short. Learn More on Y-mAbs Therapeutics' current short interest. What is a good short interest ratio for Y-mAbs Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. YMAB shares currently have a short interest ratio of 15.0. Learn More on Y-mAbs Therapeutics's short interest ratio. What is a good short interest percentage for Y-mAbs Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.35% of Y-mAbs Therapeutics' floating shares are currently sold short. Is Y-mAbs Therapeutics' short interest increasing or decreasing? Y-mAbs Therapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 4,190,000 shares, a decline of 12.7% from the previous total of 4,800,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Y-mAbs Therapeutics' float size? Y-mAbs Therapeutics currently has issued a total of 44,570,000 shares. Some of Y-mAbs Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Y-mAbs Therapeutics currently has a public float of 36,920,000 shares. How does Y-mAbs Therapeutics' short interest compare to its competitors? 11.35% of Y-mAbs Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Y-mAbs Therapeutics: Heron Therapeutics, Inc. (23.84%), Aurinia Pharmaceuticals Inc. (6.11%), Amarin Co. plc (4.38%), Mersana Therapeutics, Inc. (8.40%), Generation Bio Co. (3.86%), Twist Bioscience Co. (16.01%), Janux Therapeutics, Inc. (8.77%), Catalyst Pharmaceuticals, Inc. (5.64%), Verona Pharma plc (11.27%), Bausch Health Companies Inc. (6.18%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.11 billion), Canadian Natural Resources Limited ($4.04 billion), Suncor Energy Inc. ($3.19 billion), Aptiv PLC ($2.56 billion), Paychex, Inc. ($2.48 billion), Cencora, Inc. ($2.28 billion), Onsemi ($2.08 billion), Moderna, Inc. ($1.98 billion), Tractor Supply ($1.93 billion), and International Paper ($1.93 billion). View all of the most shorted stocks. What does it mean to sell short Y-mAbs Therapeutics stock? Short selling YMAB is an investing strategy that aims to generate trading profit from Y-mAbs Therapeutics as its price is falling. YMAB shares are trading up $1.30 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Y-mAbs Therapeutics? A short squeeze for Y-mAbs Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of YMAB, which in turn drives the price of the stock up even further. How often is Y-mAbs Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including YMAB, twice per month. The most recent reporting period available is August, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Heron Therapeutics Short Interest Data Aurinia Pharmaceuticals Short Interest Data Amarin Short Interest Data Mersana Therapeutics Short Interest Data Generation Bio Short Interest Data Twist Bioscience Short Interest Data Janux Therapeutics Short Interest Data Catalyst Pharmaceuticals Short Interest Data Verona Pharma Short Interest Data Bausch Health Companies Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:YMAB) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
